거담제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)
Expectorant Drugs Market (Drug Type: Secretion Enhancer and Mucolytics, and Dosage Form: Oral Solid, Oral Liquid, and Inhalant) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1531054
리서치사:Transparency Market Research
발행일:2024년 06월
페이지 정보:영문 156 Pages
라이선스 & 가격 (부가세 별도)
한글목차
거담제 시장 - 조사 범위
TMR의 조사 보고서 "거담제 세계 시장"은 2024-2034년 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2024년을 기준 연도, 2034년을 예측 연도로 설정하여 2018-2034년 세계 거담제 시장의 수익과 예측을 제공합니다. 또한 2024-2034년 세계 거담제 시장의 연평균 성장률(CAGR)도 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 거담제 시장을 추론했습니다.
시장 스냅샷
2023년 시장 규모
164억 달러
2034년 시장 규모
271억 달러
CAGR
4.7%
이 보고서는 세계 거담제 시장의 경쟁 환경을 조사하고 있습니다. 세계 거담제 시장에서 사업을 전개하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등이 세계 거담제 시장에서 활동하는 주요 기업의 속성입니다.
목차
제1장 서문
제2장 가정과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
소개
개요
시장 역학
세계의 시장 분석과 예측(2020-2034년)
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19에 의한 산업에 대한 영향
제6장 세계의 시장 분석과 예측 : 약물 유형별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 약물 유형별(2020-2034년)
분비촉진제
점액용해제
시장 매력 : 약물 유형별
제7장 세계의 시장 분석과 예측 : 제형별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 제형별(2020-2034년)
경구 고형제
경구 액제
흡입제
시장 매력 : 제형별
제8장 세계의 시장 분석과 예측 : 유형별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 유형별(2020-2034년)
시판약
처방약
시장 매력 : 유형별
제9장 세계의 시장 분석과 예측 : 유통 채널별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 유통 채널별(2020-2034년)
원내 약국
소매 약국
온라인 약국
시장 매력 : 유통 채널별
제10장 세계의 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별(2020-2034년)
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장 매력 : 지역별
제11장 북미의 시장 분석과 예측
제12장 유럽의 시장 분석과 예측
제13장 아시아태평양의 시장 분석과 예측
제14장 라틴아메리카의 시장 분석과 예측
제15장 중동 및 아프리카의 시장 분석과 예측
제16장 경쟁 상황
시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Abbott Laboratories
Acella Pharmaceuticals, LLC
AstraZeneca plc
Cipla Limited
Dabur India Ltd.
Glenmark Pharmaceuticals Limited
Johnson & Johnson
The Merck Group
Pfizer Inc.
The Procter & Gamble Company
Reckitt Benckiser Group PLC
Sanofi S.A.
ksm
영문 목차
영문목차
Expectorant Drugs Market - Scope of Report
TMR's report on the global expectorant drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global expectorant drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global expectorant drugs market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the expectorant drugs market.
Market Snapshot
Market Value in 2023
US$ 16.4 Bn
Market Value in 2034
US$ 27.1 Bn
CAGR
4.7%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global expectorant drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global expectorant drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global expectorant drugs market.
The report delves into the competitive landscape of the global expectorant drugs market. Key players operating in the global expectorant drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global expectorant drugs market profiled in this report.
Key Questions Answered in Global expectorant drugs Market Report:
What is the sales/revenue generated by expectorant drugs across all regions during the forecast period?
What are the opportunities in the global expectorant drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Expectorant Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global expectorant drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global expectorant drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global expectorant drugs market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Expectorant Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Expectorant Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Expectorant Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2020-2034
6.3.1. Secretion Enhancer
6.3.1.1. Potassium Citrate
6.3.1.2. Sodium Citrate
6.3.1.3. Guaiphenesin
6.3.1.4. Others (Ammonium Chloride, etc.)
6.3.2. Mucolytics
6.3.2.1. Bromhexine
6.3.2.2. Amroxol
6.3.2.3. Acetyl Cysteine
6.3.2.4. Carbocisteineurine
6.4. Market Attractiveness, by Drug Type
7. Global Expectorant Drugs Market Analysis and Forecast, by Dosage Form
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Dosage Form, 2020-2034
7.3.1. Oral Solid
7.3.1.1. Powder & Granules
7.3.1.2. Tablet
7.3.1.3. Capsule
7.3.1.4. Lozenge
7.3.2. Oral Liquid
7.3.2.1. Syrup
7.3.2.2. Solution
7.3.2.3. Suspension
7.3.2.4. Elixir
7.3.3. Inhalant
7.4. Market Attractiveness, by Dosage Form
8. Global Expectorant Drugs Market Analysis and Forecast, by Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Type, 2020-2034
8.3.1. Over-the-Counter Drugs
8.3.2. Prescription Drugs
8.4. Market Attractiveness, by Type
9. Global Expectorant Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Expectorant Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Expectorant Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2020-2034
11.2.1. Secretion Enhancer
11.2.1.1. Potassium Citrate
11.2.1.2. Sodium Citrate
11.2.1.3. Guaiphenesin
11.2.1.4. Others (Ammonium Chloride, etc.)
11.2.2. Mucolytics
11.2.2.1. Bromhexine
11.2.2.2. Amroxol
11.2.2.3. Acetyl Cysteine
11.2.2.4. Carbocisteineurine
11.3. Market Attractiveness, by Drug Type
11.4. Market Value Forecast, by Dosage Form, 2020-2034
11.4.1. Oral Solid
11.4.1.1. Powder & Granules
11.4.1.2. Tablet
11.4.1.3. Capsule
11.4.1.4. Lozenge
11.4.2. Oral Liquid
11.4.2.1. Syrup
11.4.2.2. Solution
11.4.2.3. Suspension
11.4.2.4. Elixir
11.4.3. Inhalant
11.5. Market Attractiveness, by Dosage Form
11.6. Market Value Forecast, by Type, 2020-2034
11.6.1. Over-the-Counter Drugs
11.6.2. Prescription Drugs
11.7. Market Attractiveness, by Type
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Drug Type
11.11.2. By Dosage Form
11.11.3. By Type
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Expectorant Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2020-2034
12.2.1. Secretion Enhancer
12.2.1.1. Potassium Citrate
12.2.1.2. Sodium Citrate
12.2.1.3. Guaiphenesin
12.2.1.4. Others (Ammonium Chloride, etc.)
12.2.2. Mucolytics
12.2.2.1. Bromhexine
12.2.2.2. Amroxol
12.2.2.3. Acetyl Cysteine
12.2.2.4. Carbocisteineurine
12.3. Market Attractiveness, by Drug Type
12.4. Market Value Forecast, by Dosage Form, 2020-2034
12.4.1. Oral Solid
12.4.1.1. Powder & Granules
12.4.1.2. Tablet
12.4.1.3. Capsule
12.4.1.4. Lozenge
12.4.2. Oral Liquid
12.4.2.1. Syrup
12.4.2.2. Solution
12.4.2.3. Suspension
12.4.2.4. Elixir
12.4.3. Inhalant
12.5. Market Attractiveness, by Dosage Form
12.6. Market Value Forecast, by Type, 2020-2034
12.6.1. Over-the-Counter Drugs
12.6.2. Prescription Drugs
12.7. Market Attractiveness, by Type
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Drug Type
12.11.2. By Dosage Form
12.11.3. By Type
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Expectorant Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2020-2034
13.2.1. Secretion Enhancer
13.2.1.1. Potassium Citrate
13.2.1.2. Sodium Citrate
13.2.1.3. Guaiphenesin
13.2.1.4. Others (Ammonium Chloride, etc.)
13.2.2. Mucolytics
13.2.2.1. Bromhexine
13.2.2.2. Amroxol
13.2.2.3. Acetyl Cysteine
13.2.2.4. Carbocisteineurine
13.3. Market Attractiveness, by Drug Type
13.4. Market Value Forecast, by Dosage Form, 2020-2034
13.4.1. Oral Solid
13.4.1.1. Powder & Granules
13.4.1.2. Tablet
13.4.1.3. Capsule
13.4.1.4. Lozenge
13.4.2. Oral Liquid
13.4.2.1. Syrup
13.4.2.2. Solution
13.4.2.3. Suspension
13.4.2.4. Elixir
13.4.3. Inhalant
13.5. Market Attractiveness, by Dosage Form
13.6. Market Value Forecast, by Type, 2020-2034
13.6.1. Over-the-Counter Drugs
13.6.2. Prescription Drugs
13.7. Market Attractiveness, by Type
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Drug Type
13.11.2. By Dosage Form
13.11.3. By Type
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Expectorant Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2020-2034
14.2.1. Secretion Enhancer
14.2.1.1. Potassium Citrate
14.2.1.2. Sodium Citrate
14.2.1.3. Guaiphenesin
14.2.1.4. Others (Ammonium Chloride, etc.)
14.2.2. Mucolytics
14.2.2.1. Bromhexine
14.2.2.2. Amroxol
14.2.2.3. Acetyl Cysteine
14.2.2.4. Carbocisteineurine
14.3. Market Attractiveness, by Drug Type
14.4. Market Value Forecast, by Dosage Form, 2020-2034
14.4.1. Oral Solid
14.4.1.1. Powder & Granules
14.4.1.2. Tablet
14.4.1.3. Capsule
14.4.1.4. Lozenge
14.4.2. Oral Liquid
14.4.2.1. Syrup
14.4.2.2. Solution
14.4.2.3. Suspension
14.4.2.4. Elixir
14.4.3. Inhalant
14.5. Market Attractiveness, by Dosage Form
14.6. Market Value Forecast, by Type, 2020-2034
14.6.1. Over-the-Counter Drugs
14.6.2. Prescription Drugs
14.7. Market Attractiveness, by Type
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Drug Type
14.11.2. By Dosage Form
14.11.3. By Type
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Expectorant Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2020-2034
15.2.1. Secretion Enhancer
15.2.1.1. Potassium Citrate
15.2.1.2. Sodium Citrate
15.2.1.3. Guaiphenesin
15.2.1.4. Others (Ammonium Chloride, etc.)
15.2.2. Mucolytics
15.2.2.1. Bromhexine
15.2.2.2. Amroxol
15.2.2.3. Acetyl Cysteine
15.2.2.4. Carbocisteineurine
15.3. Market Attractiveness, by Drug Type
15.4. Market Value Forecast, by Dosage Form, 2020-2034
15.4.1. Oral Solid
15.4.1.1. Powder & Granules
15.4.1.2. Tablet
15.4.1.3. Capsule
15.4.1.4. Lozenge
15.4.2. Oral Liquid
15.4.2.1. Syrup
15.4.2.2. Solution
15.4.2.3. Suspension
15.4.2.4. Elixir
15.4.3. Inhalant
15.5. Market Attractiveness, by Dosage Form
15.6. Market Value Forecast, by Type, 2020-2034
15.6.1. Over-the-Counter Drugs
15.6.2. Prescription Drugs
15.7. Market Attractiveness, by Type
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Drug Type
15.11.2. By Dosage Form
15.11.3. By Type
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Acella Pharmaceuticals, LLC
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. AstraZeneca plc
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Cipla Limited
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Dabur India Ltd.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Glenmark Pharmaceuticals Limited
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Johnson & Johnson
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. The Merck Group
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Pfizer Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. The Procter & Gamble Company
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Reckitt Benckiser Group PLC
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Sanofi S.A.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
